BRCA1-ASSOCIATED PROTEIN-1 (BAP1) MUTATIONS
Clinical trials for BRCA1-ASSOCIATED PROTEIN-1 (BAP1) MUTATIONS explained in plain language.
Never miss a new study
Get alerted when new BRCA1-ASSOCIATED PROTEIN-1 (BAP1) MUTATIONS trials appear
Sign up with your email to follow new studies for BRCA1-ASSOCIATED PROTEIN-1 (BAP1) MUTATIONS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for rare cancer: oral pill targets early mesothelioma in High-Risk patients
Disease control TerminatedThis study tests an oral medication (decitabine/cedazuridine) in people with BAP1 gene mutations who have early-stage mesothelioma that is not yet causing symptoms. The goal is to see if the drug can stop the cancer from growing or shrink it. About 9 participants will receive tre…
Matched conditions: BRCA1-ASSOCIATED PROTEIN-1 (BAP1) MUTATIONS
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 18, 2026 11:49 UTC
-
Study of experimental drug for rare mesothelioma halted before starting
Disease control TerminatedThis study was designed to test the drug alrizomadlin (APG-115) in people with BAP1 cancer syndrome who have early-stage mesothelioma that does not yet need standard treatment. The goal was to see if the drug could stabilize or improve the disease. However, the study was withdraw…
Matched conditions: BRCA1-ASSOCIATED PROTEIN-1 (BAP1) MUTATIONS
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 09, 2026 12:17 UTC